We scan new podcasts and send you the top 5 insights daily.
Dr. Alvarez-Secord explains that unlike FR-alpha or HER2 ADCs that target growth signals, B7-H4 is embedded in immune regulation. Administering a B7-H4 ADC relieves microenvironment immunosuppression while tumor cell kill releases neoantigens, creating synergy when paired with checkpoint inhibitors like dostarlimab.
Antibody-drug conjugates (ADCs) can cause immunogenic cell death, remodeling the tumor microenvironment and enhancing antigen presentation. This mechanism could potentially make PD-L1 negative ('cold') tumors responsive to immune checkpoint inhibitors, creating a strong rationale for investigating ADC-immunotherapy combinations in this patient population.
The rationale for combining ADCs with checkpoint inhibitors extends beyond additive effects. Preclinical data shows ADCs can increase T-cell infiltration into the tumor, potentially turning immunologically 'cold' tumors 'hot.' This offers a promising synergistic strategy, especially for PD-L1 negative patients who typically don't respond to immunotherapy alone.
The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.
The Begonia trial showed an ~80% response rate by combining an ADC (Dato-DXD) with immunotherapy (Durvalumab) in first-line metastatic TNBC patients, 87% of whom were PD-L1 negative. This suggests ADCs, through immunogenic cell death, may create an immune-responsive environment, expanding IO benefit beyond the traditional biomarker.
The future of GYN oncology immunotherapy is diverging. For responsive cancers like endometrial, the focus is on refining biomarkers and overcoming resistance. For historically resistant cancers like ovarian, the strategy shifts to using combinatorial approaches (e.g., CAR-NKs, vaccines) to fundamentally alter the tumor microenvironment itself, making it more receptive to an immune response.
Antibody-drug conjugates can disrupt the tumor microenvironment, leading to an influx of immune cells. This may turn an immunologically "cold" tumor "hot," creating a rationale for re-challenging with an immune checkpoint inhibitor, even if the patient's tumor previously did not respond to one.
Alpha-emitting radiopharmaceuticals physically destroy tumor cells, creating a cloud of debris that acts as a signal for the immune system. This "neoantigenic storm" helps T-cells identify and attack cancer, making checkpoint inhibitors more effective by providing a clearer target.
To combat immunosuppressive "cold" tumors, new trispecific antibodies are emerging. Unlike standard T-cell engagers that only provide the primary CD3 activation signal, these drugs also deliver the crucial co-stimulatory signal (e.g., via CD28), ensuring full T-cell activation in microenvironments where this second signal is naturally absent.
While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.
Testing antibody-drug conjugate (ADC) and immunotherapy combinations in the neoadjuvant setting is strategically superior because an intact tumor's antigen load enhances T-cell priming and immunotherapy efficacy, an advantage lost in the post-surgery adjuvant setting.